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The big conundrum for the management of 
BE is that several methods of diagnosis, moni-
toring, and treatment have evolved empirically 
without a robust evidence base.12,13 Consequent-
ly, there are issues with safety, efficacy, cost, and 
indeed patient acceptability at all stages of man-
agement. In an ideal setting, large long-term clin-
ical trials with clinically important endpoints 
would be set up to achieve generalizable data for 
application to clinical medicine. However, with a 
few exceptions including the Aspirin Esompera-
zole Chemo prevention Trial (AspECT) and Bar-
rett’s Oesophagus Surveillance Study (BOSS) tri-
als, there is insufficient concerted action, main-
ly due to funding availability, to address many 
of the key issues.10,14,15 Therefore, to address the 
big data needed for the clinical arena, we have 
Introduction Barrett esophagus (BE) is a meta-
plastic premalignant1,2 condition with inherited 
predisposition.3,4 BE is also a common condition 
affecting between 2% and 3% of adults in West-
ern countries. BE is also increasingly common in 
the Asian continent.5,6 The main reason why it is 
important to recognize and manage BE is that it 
may uncommonly give rise to an esophageal ad-
enocarcinoma (EA), which has a poor prognosis 
unless diagnosed early, usually at the preinvasive 
dysplastic stage.7-9 It is recognized that in the ma-
jority of cases of BE, the main initiating factor is 
poorly controlled gastroesophageal reflux disease 
(GERD).10,11 Therefore, the entire disease process 
is a continuum called the esophagitis-metaplasia-
-dysplasia-adenocarcinoma sequence (EMDAS).1
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We undertook two of the largest evidence-based reviews in clinical medicine to assess the rationale 
for the management of gastroesophageal reflux disease, Barrett esophagus (BE), dysplasia, and early 
invasive esophageal adenocarcinoma. These reviews involved over 150 world experts in 4 continents, 
and over 20 000 papers were assessed. Quality assessment of the publications was made using Grading 
of Recommendations Assessment, Development and Evaluation, and of over 240 questions formulated, 
we were able to answer 30% with an agreement of at least 80%. We agreed on a unique global defini-
tion of BE meaning that the presence both of hiatus hernia endoscopically and of intestinal metaplasia 
histologically should be noted. In addition, we devised an escalation and deescalation pathway for the 
management of esophagitis, metaplasia, dysplasia, and adenocarcinoma sequence. Endoscopic resection 
(ER) is recommended for visible mucosal lesions. Moreover, we endorsed the early use of ablation therapy 
for persistent dysplasia of any degree. In this regard, ER may be both diagnostic and therapeutic and 
may be sufficient even in early mucosal lesions (T1m). In conclusion, fewer people should be surveyed 
but those that do will require more detailed mapping and endoscopic interventions than currently. In 
addition, patients accumulating other potentially life-threaten-ing comorbidities should be offered ces-
sation of surveillance. In the future, chemoprevention may be the game-changing solution but results 
from large randomized trials, including AspECT and BOSS, are awaited.
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pathological diagnosis, and staging and patient 
advice.
Clinically relevant guidelines diagnosis BE is de-
fined by the endoscopic presence of columnar mu-
cosa of the esophagus. It should be stated wheth-
er intestinal metaplasia (IM) is present or absent 
above the gastroesophageal junction. The stipu-
lation that IM must be present to diagnose BE 
has several problems. Of particular note is that 
the identification of IM is subject to biopsy sam-
pling error.18,19 In many cases, benign BE needs 
just 1 expert pathologist, whereas any grade of 
suspected dysplasia needs 2 pathologists.20 In ad-
dition, the rate of progression of IM and non-IM 
mucosa to dysplasia is very similar in most case 
series. The presence and extent of the common-
ly associated hiatus hernia (HH) with BE should 
be made to avoid a false diagnosis of BE (ie, no 
BE only HH in reality) or misdiagnosis of HH (ie, 
HH smaller than reported and a segment of BE 
is also present in reality). 
Prevention There is a surfeit of research stud-
ies indicating that eating fresh vegetables, fruit, 
low-fat diets with high selenium content are as-
sociated with a lower rate of EA. However, the ev-
idence is weak and unlikely to be applicable to the 
general population. Most notably, there is a lot of 
pressure to recommend low-dose aspirin to pre-
vent EA.21-23 However, again the evidence is not 
yet suitable for application to the general popula-
tion. Data from the AspECT trial should be ready 
in 2017 to hopefully answer this question defin-
itively. Obesity is a huge independent risk factor 
for EA, although some of this could still be due 
to symptom control.24-27 In addition, the length 
of the metaplastic segment in BE is also a strong 
independent factor.28-31
devised two of the world’s largest systematic re-
views in clinical medicine to assess the evidence 
base across the entire spectrum of GERD, BE, 
dysplasia, and EA.
These systematic reviews are unique in sever-
al regards, including size, scope, methodology, 
and rigor. The BArrett’s Dysplasia CAncer Task 
Force (BADCAT) and Benign Barrett’s CAncer 
Task Force (BoB CAT) reviews assessed 12 500 
and 20 500 publications, respectively, in compari-
son with conventional reviews, which may assess 
perhaps only a few thousand papers.12,13 Further-
more, we assessed a true multidisciplinary subject 
matter all the way from gastroenterology, gastro-
intestinal surgery, epidemiology, biomarkers, ge-
nomics/genetics, endoscopy, endoscopic therapy, 
and patient/carer support. Moreover, we used a 
unique methodology including an offshore web 
platform, which could house selected citations for 
review by over 100 experts from around the world 
who could then compose relevant questions for 
clinical practice and formulate the evidence base. 
In addition, where possible, we undertook quali-
ty evaluation of the evidence, so that the plausi-
bility of any subsequent clinical statements could 
be transparently achieved.
BADCAT dealt with the rarer high-grade dys-
plasia and early invasive EA, whereas BoB CAT 
dealt with the more common benign and low-
-grade dysplasia. As a consequence, we achieved 
a global consensus of management over the en-
tire continuum of the EMDAS.
Over 300 questions were addressed by a Del-
phi mechanism16,17 in both reviews but the evi-
dence base was insufficient to address more than 
approximately one-third of them. The clinically 
relevant statements fell into prevention, early 
diagnosis, self-management, medical manage-
ment, surgical management, endoscopic screen-
ing, endoscopic surveillance, endoscopic therapy, 
FIguRE 1 The 
horizontal large blue 
arrows represent the 
common stages of 
progression of esophageal 
reflux disease. The black 
looped arrows represent 
the less common stages 
of regression to more 
benign phenotypes. The 
smaller upper boxes 
represent the risk factors 
for progression at each 
stage. The larger bottom 
boxes represent the 
clinical interventions for 
each stage. Reproduced 
from Bennett et al,13 with 
consent. 
Abbreviations: GERD, 
gastroesophageal reflux 
disease; ER, endoscopic 
resection; LGD, low-grade 
dysplasia
males at higher risk 
aged >60 y with 
uncontrolled GERD 
symptoms for >10 y
higher-risk groups (includ-
ing age > 50 y, white race, 
male sex, central obesity 
and symptoms)
lower-risk LGD: LGD on 
only 1 occasion, or LGD 
absent after 2 consecu-
tive endoscopies
higher-risk LGD: long 
segment, multifocal, 
persistent, visible 
lesion
general population
endoscopic screening 
only in higher risk group
barrett esophagus
endoscopic surveillance 
in higher-risk groups 
unless life expectancy 
is <5 y; if visible le-
sion, diagnostic ER, 
then ablate
lower-risk Lgd
LGD on a single occa-
sion, endoscopy at 6–12 
months; absence of 
LGD after 2 consecutive 
endoscopies: revert to 
routine practice
higher-risk Lgd
ablative therapy with 
follow-up; if visible 
lesion: ER (+ ablative 
therapy) and follow-up 
surveillance
symptomatic esophagitis Barrett esophagus lower-risk LGD higher-risk LGD
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such as ischemic heart disease (IHD) and broncho-
pneumonia, rather than from EA, is more com-
mon, and therefore, medical management should 
focus on them in a holistic ethos.
stratification  When low-grade dysplasia is iden-
tified and has high-risk features such as multifo-
cality in longer BE segments and persistence on 
several occasions, patients should have manage-
ment intensified accordingly as they are more like-
ly to progress. Similarly, when low-grade dyspla-
sia is present on only one occasion and is unifo-
cal, patients should revert to normal surveillance 
after a second confirmatory endoscopy (carried 
out within 6 to 12 months).13,31
Endoscopic therapy Endoscopic resection and 
radio -frequency ablation should only be used 
where dysplasia or neoplasia is already diag-
nosed histologically or strongly suspected by 
the presence of visible irregularities in the mu-
cosal surface.36-42
Pathological diagnosis and staging To ensure ac-
curate reporting of BE and dysplasia, it is recom-
mended that in benign cases there is little un-
certainty in diagnosis with the reliance on only 
1 trained gastrointestinal pathologist. Howev-
er, when any degree of dysplasia is suspected, 
at least 2 trained specialist gastrointestinal pa-
thologists are needed to ascertain the severity 
of the lesion. The use of pathological proformas 
have been recommended to ensure reproducibil-
ity of reports.13,18-20
Patient advice It is important to recognize that 
the first clinician seeing the patient may poten-
tially bias them to the best course of action. There-
fore, it is essential that a balanced risk–benefit of 
both the disease progression and therapy is ex-
plained in a careful ordered sequence so as to al-
low reflective questioning by the patient. Patient 
information should be offered by mixed media in-
cluding face-to-face meetings, the Internet, pam-
phlets, and other patients with experience via pa-
tient support groups.13
Conclusions In conclusion, we have achieved a 
worldwide definition of BE for the first time. This 
is important as it means that investigators can di-
agnose BE similarly regardless of geographic dis-
tribution. In essence, the presence of intestinal 
metaplasia is an important pathological feature 
but it is no longer an essential pathological crite-
rion that needs to be met. In addition, we indicate 
that the presence and length of any HH should be 
noted to avoid false diagnosis of BE or misdiag-
nosis of HH. Specifically, failure to recognize an 
HH may lead to overestimation of BE or indeed 
a diagnosis of BE when none exists.
We have also produced a novel bidirectional es-
calation and deescalation pathway for the EMDAS 
to inform appropriate management of all stages 
of the disease. This means that there is now an 
Early diagnosis There is an abundance of ad-
vanced diagnostic endoscopic methods avail-
able. However, there is insufficient evidence to 
recommend them for routine use outside select-
ed centers where ongoing evaluation of their effi-
cacy is possible. Specifically, even advanced mag-
nification or visualization methods with target-
ed biopsies should only be used in specialist cen-
ters with adequate training on their suitability.13
biomarkers There were no accepted laborato-
ry biomarkers that could improve standard his-
topathological methods. Interestingly, both p53 
and p16 immunocytochemistry were felt to help 
stratify prognostication of cancer risk.31-33
Medical management There is currently no strong 
evidence to recommend proton-pump inhibitors 
(PPIs) for the prevention of EA, although there is 
a strong negative association.13 Randomized tri-
als, especially AspECT will report in 2017 on the 
value of using high-dose PPIs versus low-dose 
PPIs in the prevention of EA.34-36 Until then, em-
pirical advice would be to minimize symptomat-
ic and nonsymptomatic reflux with an effective 
PPI dose twice daily. If symptoms occur or endo-
scopic damage is apparent, higher-dose PPI ther-
apy should be employed twice daily.
surgical management Surgical repair of the low-
er esophageal sphincter cannot be recommend-
ed for cancer prevention,13,34 although it may be 
a useful option for patients who do not want to 
take PPIs for more than 5 years (although some 
patients may still require PPI therapy after such 
surgery). The common side effects of PPIs include 
diarrhea, liver toxicity, skin rashes; more recently, 
interference with clopidogrel activity, osteoporo-
sis, and B12 malabsorption have been also associ-
ated but remain of clinical uncertainty.
Endoscopic screening Endoscopic screening 
whether by endoscopic or nonendoscopic means 
is not recommended owing to low sensitivity and 
specificity. Even Markov modeling has suggest-
ed its unsuitability for routine clinical use. There 
is one exception where men over 60 years of age 
with a history of reflux of 10 years or longer are 
likely to have an appreciable risk of BE on endos-
copy of between 20% to 50%.13
Endoscopic surveillance The risk of progression 
for average risk patients with BE is very low. We 
make no recommendation whether to survey or 
not. There will be a report on BOSS addressing 
this issue in 2020.13 Specifically, this randomized 
trial assesses 2-year endoscopic surveillance ver-
sus endoscopy at time of need. However, when life 
expectancy is less than 5 years, the risk-benefit ra-
tio of endoscopy in elderly patients (>80 years old) 
becomes a vital factor.13 Specifically, the serious 
adverse complication rate of endoscopy with seda-
tion may range from 1 in 500 to 1 in 300 individ-
uals. In BE patients, death from other conditions 
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